Understand the source comparison
Best Peptides for Autoimmune Conditions: Detailed Comparison
The table below compares the three most researched peptides for autoimmune conditions by mechanism, receptor target, disease applicability, and typical research dosing protocols. Each peptide intervenes at a different immune control point. Selecting the correc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the three most researched peptides for autoimmune conditions by mechanism, receptor target, disease applicability, and typical research dosing protocols. Each peptide intervenes at a different immune control point. Selecting the correct peptide requires matching the mechanism to the disease's underlying immune dysregulation.
- Thymosin Alpha-1
- Promotes T-regulatory cell differentiation and dendritic cell maturation via TLR-2/TLR-9 signalling
- Toll-Like Receptors (TLR-2, TLR-9)
- Systemic autoimmune (RA, lupus, autoimmune hepatitis), B-cell-mediated thyroid disease
- 1.6–3.2mg subcutaneous twice weekly
- ~2 hours (immunomodulatory effects persist 72–96 hours)
- Best for systemic T-cell and B-cell dysregulation. Restores immune tolerance rather than suppressing immunity
- VIP (Vasoactive Intestinal Peptide)
- Reduces TNF-alpha, IL-6, IL-17 via VPAC receptor activation; increases IL-10 anti-inflammatory signalling
- VPAC1 and VPAC2 (G-protein coupled receptors)
- Mucosal autoimmune (IBD, sarcoidosis, asthma), CNS inflammation
- 200–400mcg intranasal daily OR 25–50mcg/kg subcutaneous
- <2 minutes plasma (intranasal bypasses hepatic degradation)
- Best for gut, lung, and CNS inflammation. Works where mucosal immune dysregulation drives disease
- LL-37
- Neutralises bacterial endotoxin (LPS), promotes epithelial barrier repair, downregulates NF-kappa-B in macrophages
- Direct LPS binding, TLR-4 modulation, formyl peptide receptor-2
- Barrier dysfunction autoimmune (IBD, atopic dermatitis, psoriasis)
- 5–10mg subcutaneous daily
- ~6 hours
- Best for conditions where epithelial barrier breakdown drives immune activation. Dual action on repair and inflammation
- This comparison clarifies that no single peptide is 'best' universally. The correct choice depends on whether the autoimmune condition is driven by adaptive immune dysregulation (thymosin alpha-1), mucosal cytokine storms (VIP), or barrier dysfunction allowing microbial translocation (LL-37). Research protocols combining peptides from different categories show additive benefit when disease phenotypes overlap, such as IBD with both barrier dysfunction and mucosal T-cell hyperactivity.